Litcius/Paper detail

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

Eun-Sil Sung, Minkyung Ko, Ju‐young Won, Yunju Jo, Eun Young Park, Hyun Joo Kim, Eun‐Ji Choi, Ui-jung Jung, Jaehyoung Jeon, Youngkwang Kim, Hyejin Ahn, Dasom Choi, Seunghyun Choi, Youngeun Hong, Hye-Young Park, Hanbyul Lee, Yong-Gyu Son, Kyeongsu Park, Jonghwa Won, Soo Jin Oh, Seonmin Lee, Kyu‐pyo Kim, Changhoon Yoo, Hyun Kyu Song, Hyung‐seung Jin, Jaeho Jung, Yoon Park

2022Molecular Therapy74 citationsDOIOpen Access PDF

Topics & Concepts

EffectorBlockadeImmune checkpointCancer researchImmune systemPD-L1AntibodyCell biologyProgrammed cell deathT cellBiologyReceptorImmunologyChemistryImmunotherapyApoptosisBiochemistryCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation | Litcius